If President Trump cracks down on drug price inflation, these pharma and biotech offenders could be in big trouble.
The stun gun maker follows several other companies that have changed their identity to reflect a new corporate mission.
Rumors that this Apple supplier has been designed out of the iPhone 8 may not be correct.
It's a risk that may not materialize for a decade or more, but it's there.
Cirrus Logic, Analog Devices, and Skyworks Solutions all offer indirect ways to invest in Apple’s growth.
Investors should benefit from these biotechs' cholesterol drugs.
Garmin, Taser, and Ambarella could be better wearable bets than GoPro or Fitbit.
Qualcomm, TI, TSMC, Analog Devices, and Broadcom all give you decent exposure to Apple while paying solid dividends.
The Medicines Company is developing a new drug that could give Amgen's Repatha a run for its money in lowering bad cholesterol levels.
Is Brian Krzanich taking too much heat for Intel’s lackluster growth?